Cargando…

Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent

PURPOSE: Currently, there is a number of successfully implemented local hemostatic agents for external bleedings in forms of wound dressings and other topical materials. However, little has been done in the field of intravenous hemostatic agents. Here, we propose a new procedure to fabricate biocomp...

Descripción completa

Detalles Bibliográficos
Autores principales: Prilepskii, Artur, Schekina, Alexandra, Vinogradov, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681571/
https://www.ncbi.nlm.nih.gov/pubmed/31534321
http://dx.doi.org/10.2147/NSA.S204621
_version_ 1783441749079752704
author Prilepskii, Artur
Schekina, Alexandra
Vinogradov, Vladimir
author_facet Prilepskii, Artur
Schekina, Alexandra
Vinogradov, Vladimir
author_sort Prilepskii, Artur
collection PubMed
description PURPOSE: Currently, there is a number of successfully implemented local hemostatic agents for external bleedings in forms of wound dressings and other topical materials. However, little has been done in the field of intravenous hemostatic agents. Here, we propose a new procedure to fabricate biocompatible protein nanocontainers (NCs) for intravenous injection allowing magneto-controllable delivery and short-term release of the hemostatic agent ε-aminocaproic acid (EACA). METHODS: The nanocontainers were synthesized by the desolvation method from bovine serum albumin (BSA) using methanol without any further crosslinking. Polyethylene glycol (PEG) was used both as a stabilization agent and for size control. Characterization of nanocontainers was performed by the transmission and scanning electron microscopy, dynamic light scattering, X-ray diffraction, and FTIR spectroscopy. Cytotoxicity was estimated using MTT assay. The dopant release from nanocontainers was measured spectrophotometrically using rhodamine B as a model molecule. The specific hemostatic activity was assessed by analyzing clot lysis and formation curve (CloFAL). Moreover, the ability for magneto targeting was estimated using the original flow setup made of a syringe pump and silicon contours. RESULTS: Fabricated nanocontainers had an average size of 186±24 nm and were constructed from building blocks–nanoparticles with average size ranged from 10 to 20 nm. PEG shell was also observed around nanocontainers with thickness 5–10 nm. NCs were proved to be completely non-cytotoxic even at concentrations up to 8 mg BSA/mL. Uptake capacity was near 36% while release within the first day was 17%. The analysis of the CloFAL curve showed the ability of NCs to inhibit the clot lysis successfully, and the ability of magneto targeting was confirmed under flow conditions. CONCLUSION: The ability of synthesized NCs to deliver and release the therapeutic drug, as well as to accumulate at the desired site under the action of the magnetic field was proved experimentally.
format Online
Article
Text
id pubmed-6681571
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66815712019-09-18 Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent Prilepskii, Artur Schekina, Alexandra Vinogradov, Vladimir Nanotechnol Sci Appl Original Research PURPOSE: Currently, there is a number of successfully implemented local hemostatic agents for external bleedings in forms of wound dressings and other topical materials. However, little has been done in the field of intravenous hemostatic agents. Here, we propose a new procedure to fabricate biocompatible protein nanocontainers (NCs) for intravenous injection allowing magneto-controllable delivery and short-term release of the hemostatic agent ε-aminocaproic acid (EACA). METHODS: The nanocontainers were synthesized by the desolvation method from bovine serum albumin (BSA) using methanol without any further crosslinking. Polyethylene glycol (PEG) was used both as a stabilization agent and for size control. Characterization of nanocontainers was performed by the transmission and scanning electron microscopy, dynamic light scattering, X-ray diffraction, and FTIR spectroscopy. Cytotoxicity was estimated using MTT assay. The dopant release from nanocontainers was measured spectrophotometrically using rhodamine B as a model molecule. The specific hemostatic activity was assessed by analyzing clot lysis and formation curve (CloFAL). Moreover, the ability for magneto targeting was estimated using the original flow setup made of a syringe pump and silicon contours. RESULTS: Fabricated nanocontainers had an average size of 186±24 nm and were constructed from building blocks–nanoparticles with average size ranged from 10 to 20 nm. PEG shell was also observed around nanocontainers with thickness 5–10 nm. NCs were proved to be completely non-cytotoxic even at concentrations up to 8 mg BSA/mL. Uptake capacity was near 36% while release within the first day was 17%. The analysis of the CloFAL curve showed the ability of NCs to inhibit the clot lysis successfully, and the ability of magneto targeting was confirmed under flow conditions. CONCLUSION: The ability of synthesized NCs to deliver and release the therapeutic drug, as well as to accumulate at the desired site under the action of the magnetic field was proved experimentally. Dove 2019-07-30 /pmc/articles/PMC6681571/ /pubmed/31534321 http://dx.doi.org/10.2147/NSA.S204621 Text en © 2019 Prilepskii et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Prilepskii, Artur
Schekina, Alexandra
Vinogradov, Vladimir
Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
title Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
title_full Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
title_fullStr Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
title_full_unstemmed Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
title_short Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
title_sort magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681571/
https://www.ncbi.nlm.nih.gov/pubmed/31534321
http://dx.doi.org/10.2147/NSA.S204621
work_keys_str_mv AT prilepskiiartur magneticallycontrolledproteinnanocontainersasadrugdepotforthehemostaticagent
AT schekinaalexandra magneticallycontrolledproteinnanocontainersasadrugdepotforthehemostaticagent
AT vinogradovvladimir magneticallycontrolledproteinnanocontainersasadrugdepotforthehemostaticagent